BNTX Stock - BioNTech SE
Unlock GoAI Insights for BNTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.75B | $3.82B | $17.31B | $18.98B | $482.30M |
| Gross Profit | $2.21B | $3.22B | $14.32B | $16.07B | $423.00M |
| Gross Margin | 80.3% | 84.3% | 82.7% | 84.7% | 87.7% |
| Operating Income | $-1,314,300,000 | $690.40M | $12.64B | $15.28B | $-82,400,000 |
| Net Income | $-665,300,000 | $930.30M | $9.43B | $10.29B | $15.20M |
| Net Margin | -24.2% | 24.4% | 54.5% | 54.2% | 3.2% |
| EPS | $-2.77 | $3.87 | $38.08 | $43.87 | $0.06 |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 5th 2025 | H.C. Wainwright | Reiterated | Buy | $145← $134 |
| May 29th 2025 | Goldman | Initiation | Neutral | $110 |
| March 13th 2025 | Citigroup | Initiation | Buy | $145 |
| January 10th 2025 | Truist | Initiation | Buy | $172 |
| December 11th 2024 | Wells Fargo | Initiation | Overweight | $170 |
| December 2nd 2024 | BMO Capital Markets | Reiterated | Outperform | - |
| November 19th 2024 | Berenberg | Initiation | Buy | $130 |
| November 19th 2024 | Evercore ISI | Upgrade | Outperform | $125← $110 |
| November 8th 2024 | Goldman | Upgrade | Buy | $137← $90 |
| September 24th 2024 | Morgan Stanley | Upgrade | Overweight | $145← $93 |
| September 17th 2024 | Jefferies | Upgrade | Buy | $150← $96 |
| September 16th 2024 | JP Morgan | Upgrade | Neutral | $125← $91 |
| August 7th 2024 | Deutsche Bank | Upgrade | Buy | $95 |
| August 2nd 2024 | HSBC Securities | Upgrade | Buy | - |
| May 14th 2024 | Evercore ISI | Initiation | In-line | $100 |
Earnings History & Surprises
BNTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 9, 2026 | $-0.57 | — | — | — |
Q1 2026 | Mar 9, 2026 | $-0.57 | — | — | — |
Q4 2025 | Nov 3, 2025 | $0.75 | $-0.14 | -118.7% | ✗ MISS |
Q3 2025 | Aug 4, 2025 | $-1.31 | $-1.82 | -38.9% | ✗ MISS |
Q2 2025 | May 5, 2025 | $-2.77 | $-1.82 | +34.3% | ✓ BEAT |
Q4 2024 | Dec 31, 2024 | — | $1.12 | — | — |
Q4 2024 | Nov 4, 2024 | $-1.26 | $0.89 | +170.6% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-2.16 | $-3.62 | -67.6% | ✗ MISS |
Q2 2024 | May 6, 2024 | $-0.82 | $-1.42 | -73.2% | ✗ MISS |
Q4 2023 | Dec 31, 2023 | — | $2.09 | — | — |
Q4 2023 | Nov 6, 2023 | $-0.53 | $0.73 | +237.7% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.75 | $-0.86 | -14.7% | ✗ MISS |
Q2 2023 | May 8, 2023 | $0.18 | $2.20 | +1122.2% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $9.97 | — | — |
Q4 2022 | Nov 7, 2022 | $3.66 | $7.04 | +92.3% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $7.69 | $7.31 | -4.9% | ✗ MISS |
Q2 2022 | May 9, 2022 | $9.14 | $15.98 | +74.8% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $13.82 | — | — |
Q4 2021 | Nov 9, 2021 | $11.79 | $14.56 | +23.5% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $8.35 | $12.98 | +55.4% | ✓ BEAT |
Latest News
'FDA Chief Says No Plans To Put Boxed Warning On Covid Vaccines' - Bloomberg News
📈 PositiveReuters Issues Correction: U.S. FDA Says "Doing A Thorough Investigation, Across Multiple Age Groups, Of Deaths Potentially Related To Covid Vaccines"
📉 NegativeBloomberg: FDA Probes If Covid Shots Might Be Linked to Deaths of Adults
📉 NegativeBioNTech And Bristol Myers Report Early Data For New Triple-Negative Breast Cancer Treatment
📈 PositiveBioNTech, OncoC4 On Saturday, Announced Clinically Meaningful Overall Survival Benefit For Selective Treg Modulator Gotistobart In Patients With Previously Treated Squamous Non-Small Cell Lung Cancer
📈 PositiveBioNTech Minimum Condition in CureVac Exchange Offer Has Been Satisfied
📈 PositiveShares of vaccine stocks are trading lower after reports indicating Center for Biologics Evaluation and Research Director Vinay Prasad plans to tighten how vaccines win federal approval, claiming links to child deaths.
📉 NegativePfizer Cuts Share Stake In BioNTech By 54.7% To 1.66M Sponsored ADSs; Change In Holdings Are As Of Sept. 30, 2025 And Compared With The Previous Quarter Ended As Of June, 30, 2025.
📉 NegativeBioNTech shares are trading lower after Bloomberg reported that Pfizer plans to sell its stake in the company.
📉 NegativeReported Earlier: 'Pfizer to Sell Stake in Pandemic Vaccine Partner BioNTech'- Bloomberg News
➖ Neutral4 stocks to watch on Thursday: DIS, RIO, JD, BNTX
➖ NeutralHC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140
📈 PositiveUBS Maintains Neutral on BioNTech, Raises Price Target to $117
➖ NeutralBioNTech Raises FY2025 Sales Guidance from $1.787B-$2.314B to $3.040B-$3.274B
📈 PositiveBioNTech Q3 EPS $(0.14) Misses $0.75 Estimate, Sales $1.776B Beat $1.190B Estimate
➖ Neutral'US Fires Top Health Official Who Opposed Widely Used Covid Shots' -Bloomberg
📉 NegativeJP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120
➖ NeutralBioNTech Commences Public Exchange Offer For All Outstanding Shares Of CureVac; CureVac Shareholders Receive ~$5.46 In BioNTech ADSs For Each CureVac Share
📈 PositiveMorgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $131
➖ Neutral'Exclusive: RFK Jr cancelled mRNA research — but the US military is still funding it'- Nature
➖ NeutralFrequently Asked Questions about BNTX
What is BNTX's current stock price?
What is the analyst price target for BNTX?
What sector is BioNTech SE in?
What is BNTX's market cap?
Does BNTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BNTX for comparison